Skip to main content

Table 4 Sensitivity to clinically approved antineoplastic agents potentiated by cytochalasin B against multidrug resistant SKVLB1 human ovarian carcinoma

From: Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro

Time of exposure (Hours) 13.5 33
IC concentrations (μM) IC90 FS IC90 FS
Doxorubicin
 0 μM Cytochalasin B 5 - 5 -
 0.15 μM Cytochalasin B 2.5 2 2.5 2
 0.60 μM Cytochalasin B 1.3 4 1.3 4
Paclitaxel
 0 μM Cytochalasin B >40 - 40 -
 0.15 μM Cytochalasin B 20 2 5 8
 0.60 μM Cytochalasin B 15 2.5 4 10
  1. FS fold sensitization